

1 **Maternal and Neonatal Colonization with Multidrug Resistant and Extended** 2 **Spectrum β -Lactamase Producing *Escherichia coli* and *Klebsiella pneumoniae*** 3 **in a Cameroonian Labour Ward**

4 Axelle Njeuna¹, Luria Leslie Founou^{1,2,3,4,5*}, Raspail Carrel Founou^{3,4,6,7}, Patrice Landry
5 Koudoum^{6,7}, Aurelia Mbossi², Ariel Blocker⁴, Stephen D. Bentley^{8,9}, Lucien Etame Sone^{1,10}

8 ¹Department of Biomedical Sciences, Higher Institute of Medical Technology, Yaoundé Cameroon

9 ²Reproductive, Maternal, New-born and Child Health (ReMARCH) Research Unit, Research Institute of
10 Centre of Expertise and Biological Diagnostic of Cameroon (CEDBCAM-RI), Yaoundé, Cameroon

11 ³Antimicrobial Research Unit, School of Health Sciences, College of Health Sciences, University of
12 KwaZulu-Natal, Durban, South Africa

13 ⁴AMR Ambassador Network, Amsterdam, Netherlands

14 ⁵Bioinformatics & Applied Machine Learning Research Unit, EDEN Biosciences Research Institute
15 (EBRI), EDEN Foundation, Yaoundé Cameroon

16 ⁶Faculty of Medicine and Pharmaceutical Sciences, Department of Microbiology-Haematology and
17 Immunology, University of Dschang, Dschang, Cameroon

18 ⁷Antimicrobial Resistance and Infectious Diseases (ARID) Research Unit, Research Institute of Centre of
19 Expertise and Biological Diagnostic of Cameroon (CEDBCAM-RI), Yaoundé,
20 Cameroon

21 ⁸Parasites and Microbes, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA,
22 United Kingdom

23 ⁹Department of Pathology, University of Cambridge, Cambridge, United Kingdom

24 ¹⁰Institute of Medical Research and Studies of Medicinal Plant (IMPM), Ministry of Scientific Research
25 and Innovation, Yaoundé, Cameroon

27 ***Corresponding author:**

28 Dr Luria Leslie Founou

29 REMARCH

30 CEDBCAM-RI

31 Yaoundé, Cameroon

32 Email: luriafounou@gmail.com

33 **Running title:** MDR and ESBL bacteria in mothers and neonates

34 **Word count: 4536**

35 **Number of figures: 5**

36 **Keywords:** Neonatal mortality; *Escherichia coli*; *Klebsiella pneumoniae*; One Health; antibiotic
37 resistance; multi-drug resistance

41 **ABSTRACT**

42 **Background:** *Escherichia coli* and *Klebsiella pneumoniae* rank among the primary bacterial
43 culprits in neonatal infections and fatalities in sub-Saharan Africa. This study sought to
44 characterize the phenotypic and genotypic features of *Escherichia coli* and *Klebsiella*
45 *pneumoniae* in a labour ward in Yaoundé, Cameroon.

46 **Methods:** A prospective and cross-sectional study spanning five months, from February 21 to
47 June 30, 2022. Recto-vaginal swabs were obtained from expectant mothers, and nasopharyngeal
48 swabs were collected from their babies. The samples were cultured on eosin methylene blue agar
49 and isolates identified using the Enterosystem 18R kit. Extended-spectrum β -lactamase (ESBL)
50 production was assessed using CHROMAgar ESBLTM and the double disc synergy test.
51 Antibiotic susceptibility was determined by the Kirby-Bauer disk diffusion method. Polymerase
52 chain reaction (PCR) was employed to detect β -lactamase genes *bla_{SHV}*, *bla_{CTX-M}* and *bla_{TEM}*.
53 ERIC-PCR was used to assess the clonal relatedness of isolates.

54 **Results:** *E. coli* was predominantly found in pregnant women (81%) and neonates (55%) while
55 *K. pneumoniae* predominated in healthcare workers. Almost all pregnant women (90%) were
56 colonized by one or more multi-drug resistant (MDR) isolates with 52% being concomitantly
57 ESBL producers. Altogether, 22 neonates were positive for *E. coli* and/or *K. pneumoniae* and 19
58 (91%) were colonized by a MDR isolate. The *bla_{CTX-M}* (75%) was the leading β -lactamase gene
59 detected.

60 **Conclusion:** Our study suggests that MDR- and ESBL-*E. coli* and *K. pneumoniae* are circulating
61 at high prevalence in labour Yaoundé. It emphasizes the necessity for strict infection prevention
62 and control measures in conjunction with effective antimicrobial stewardship in the country.

64 INTRODUCTION

65 Despite remarkable advances made the past decades to reduce the number of neonatal deaths
66 globally, many newborns continue to die every year mostly from preventable causes. In 2021,
67 globally 2.3 million children died before turning one month old, of these deaths 1 million (27.5
68 deaths per 1000 live births) were in neonates from sub-Saharan Africa (1). In Cameroon, the
69 neonatal mortality rate was 23.19/1000 live births in 2021 (2), greatly exceeding United Nations
70 Sustainable Development Goal (SDG) 3.2.2 that aims for countries to have ≤ 12 neonatal
71 deaths/1000 live births by 2030 (3, 4). By 2035, it is estimated that there would be an extra 49
72 million newborn deaths, 52 million stillbirths, 5 million maternal deaths, and 99 million children
73 with disabilities if significant efforts are not made (8). Therefore, continuing to reduce newborn
74 mortality is crucial to improving infant survival. Prioritizing research appropriately and creating
75 plans for infection prevention and control measures require a deeper understanding of the
76 aetiology and transmission mechanisms of neonatal infections.

77 Neonatal sepsis remains an important cause of neonatal mortality worldwide, particularly in sub-
78 Saharan Africa (5). The escalation of antibiotic resistance further exacerbates this problem (6, 7).
79 Multi-drug resistant (MDR) bacteria, especially extended-spectrum β -lactamase producing
80 *Enterobacteriales* (ESBL-E) are pathogens of critical priority for research and among the leading
81 causes of neonatal infections especially in pre-term infants (6, 7). A systematic review revealed
82 that *Escherichia coli* and *Klebsiella pneumoniae* were among the most frequent causes of
83 bacterial neonatal sepsis in sub-Saharan Africa with 66% of neonatal sepsis and meningitis cases
84 caused by antibiotic-resistant *E. coli* and *K. pneumoniae* between 2008 and 2018 in the region
85 (5). Neonates can be exposed to ESBL-E before delivery (after rupture of the amniotic
86 membrane) or during delivery, establishing maternal rectovaginal ESBL-E carriage as an

87 important predictor of neonatal carriage/infection (8, 9). Consequently, neonatal bacterial
88 infections, primarily acquired at the time of delivery through maternal-neonatal transmission, are
89 a leading preventable cause of morbidity and mortality (10).

90 Notwithstanding, there are currently no policies implemented for routine prenatal screening of
91 antibiotic-resistant bacteria in Cameroon. Moreover, antibiotic usage is not well-regulated, and
92 there is a dearth of information regarding the burden of MDR- and ESBL-*E. coli* and *K.*
93 *pneumoniae* circulating strains in mother-neonate dyads in the country. Finally, the role of
94 maternal carriage of resistant bacteria remains unknown in Cameroon, and it is unclear to what
95 extent it could contribute to neonatal infection in the country. To the best of our knowledge, no
96 study focusing on the burden, phenotypic and genetic profiles as well as transmission of
97 antibiotic resistant *E. coli* and *K. pneumoniae* in mother-neonate dyads has been carried out so
98 far in Cameroon. This study therefore ascertains the phenotypic and genotypic diversity of *E.*
99 *coli* and *K. pneumoniae* in a labour ward of a hospital in Yaoundé with a view to generating
100 knowledge and informing evidence-based strategies for better management of maternal and
101 neonatal infections.

102 MATERIALS AND METHODS

103 This study is reported following the Strengthening the Reporting of Observational Studies in
104 Epidemiology for Newborn Infection (STROBE-NI) (11).

105 1. Study design and study site

106 A cross-sectional, prospective, and analytical study was conducted over a period of five months
107 from February to June 2022. Sample collection was carried out during five weeks (from February
108 21 to March 25, 2022) in a confessional hospital in Yaoundé specializing in the care of pregnant

109 women from pregnancy to delivery. This hospital provides antenatal care services for 700
110 pregnant women and practices around 450 deliveries per month.

111 **2. Study population**

112 The primary study population consisted of pregnant women with a gestational age above 32
113 weeks who attended the labour room of the selected hospital for delivery regardless of age,
114 ethnicity, or HIV status. Mothers who were mentally unstable or engaged in health prognostic
115 were excluded from the study. The secondary population was the babies of the included pregnant
116 women. However, babies with a poor health prognosis were excluded from the study. Healthcare
117 workers working or visiting the maternity ward were also collected. The hospital environment of
118 the maternity ward, delivery room, and postpartum room was also considered in this study.

119 **3. Recruitment and sample collection**

120 Due to technical constraints, a saturation of sampling was implemented during the five-week
121 sample collection period. All mothers and HCWs who met the inclusion criteria provided oral
122 and written informed consent. A questionnaire was administered, and socio-demographic and
123 clinical data were collected using Epicollect® 5 software (Centre for Genomic Pathogen
124 Surveillance, Oxford, UK).

125 Samples were collected using sterile Amies swabs. Recto-vaginal swabs were collected from
126 pregnant women prior to delivery, while nasopharyngeal swabs were taken from babies right
127 after birth or before their first bath (less than 24 hours). The hands of the healthcare workers were
128 also swabbed, as were predefined hospital environment sites (Table S1). All samples were
129 transported within 12 hours to the Research Institute of the Centre of Expertise and Biological
130 Diagnostics of Cameroon ([CEDBCAM-RI](#)).

131

132 **4. Ethical considerations**

133 A research permit was granted from the Ministry of Scientific Research and Innovation
134 (N°0022/MINRESI/B00/C00/C10/C13) prior to the implementation of the study. This research
135 was approved by the National Ethics Committee for Human Health Research (No.
136 2021/07/1386/CE/CNERSH/SP) and the Ethical Committee of the University of Douala (No.
137 3190 CEI-UDo/06/2022/M). Oral and written informed consent to participate in this study was
138 provided by participants or the legal guardian or nearest relative of the babies. Participants were
139 anonymized and their and their information encoded before analysis to ensure confidentiality.

140 **5. Laboratory analysis**

141 **5.1.Bacterial isolation and identification**

142 All samples were cultured on Eosin-Methylene Blue (EMB) agar and incubated in a
143 bacteriological incubator at 37°C for 18 to 24 hours. After incubation, all growing colonies were
144 phenotypically identified with the Enterosystem 18R kit as per the manufacturer's instructions.
145 The screening of ESBL-producing isolates was performed with the chromogenic medium
146 CHROMAgar ESBL™ (CHROMAgar, Paris, France).

147 **5.2.Antimicrobial Susceptibility Testing**

148 The Kirby-Bauer disk diffusion method was used to evaluate the susceptibility of *E. coli* and *K.*
149 *pneumoniae* isolates against a panel of 12 antibiotics (Oxoid®), including amoxicillin-clavulanic
150 acid (AMC, 30 µg), cefuroxime (CXM, 30 µg), ceftazidime (CAZ, 30 µg), cefotaxime (CTX, 30
151 µg), cefepime (FEP, 30 µg), cefoxitin (FOX, 30 µg), amikacin (AK, 30 µg), gentamicin (GEN,
152 30 µg), ciprofloxacin (CIP, 5 µg), chloramphenicol (C, 30 µg), doxycycline (DOX, 30 µg), and
153 trimethoprim-sulfamethoxazole (TMP/SXT, 25µg) . For all antibiotics, the EUCAST (12) clinical
154 breakpoints were used for interpretation. But for doxycyclin, and trimethoprim-

155 sulfamethoxazole, the CLSI 2020 (13) guideline was used. Multidrug resistance (MDR), which is
156 the resistance of bacteria to at least one antibiotic from three or more families of antibiotics, was
157 also evaluated.

158 **5.3. Genotypic analysis**

159 **5.3.1. Genomic amplification of *bla_{SHV}*, *bla_{CTX-M}* and *bla_{TEM}***

160 The genomic DNA of *E. coli* and *K. pneumoniae* isolates was extracted using a modified boiling
161 method (14). After incubation, the suspension was centrifuged at 9500 rpm for 5 min, and then
162 300 µL of the supernatant having DNA was transferred to a new Eppendorf tube and stored at -30
163 °C for future use. The detection of the *bla_{SHV}* gene was performed by conventional PCR in a 10
164 µL reaction mixture consisting of 5 µL of DreamTaq™ Green Polymerase 2X (ThermoFisher
165 Scientific™, Vilnius, Lithuania), 2.8 µL of nuclease-free water, 0.1 µL of each forward and
166 reverse primer [10 µM], and 2 µL of template DNA. Likewise, detection of *bla_{CTX-M}* and *bla_{TEM}*
167 genes was performed by multiplex-PCR (M-PCR) in a 10 µL reaction mixture consisting of 5 µL
168 of DreamTaq Green Polymerase 2X (ThermoFisher Scientific™, Vilnius, Lithuania), with 0.1 µL
169 of each forward (CTX-Mu1 and TEM-F) and reverse (CTX-Mu2 and TEM-R) primers [50 µM]
170 and 2 µL of DNA. Primer sequences previously reported [9], were all synthesized by Inqaba
171 Biotec West Africa. All amplification reactions took place in a BIO-RAD T100 thermal cycler
172 (Bio-Rad Laboratories, Marnes-la-Coquette, France) following the programming conditions
173 described previously (14).

174 **5.3.2. Agarose gel electrophoresis and DNA visualization**

175 After amplification, DNA electrophoresis was performed on a 1.5% (wt/vol) agarose gel run at
176 90 V for 45 min with a molecular ladder of 100 bp (New England Biolabs, MA, USA). The gel
177 was then stained in an ethidium bromide solution (0.5 µg/mL) for 15 min and briefly unstained

178 with water. The amplicons were visualized under UV light using a G-BOX Chemi XL gel
179 documentation system (Syngene, Cambridge, UK). Figure 1 shows the visualization of amplicons
180 from various samples with the targeted ESBL genes.

181 **5.3.3. Genotypic relatedness**

182 Enterobacterial Repetitive Intergenic Consensus-Polymerase Chain Reaction (ERIC-PCR) was
183 used to show the clonal relatedness between the isolates originating from mother-baby pairs,
184 HCWs, and the environment. The primers ERIC1 5'ATGTAAGCTCCTGGGGATTAC3' and
185 ERIC2 5'AAGTAAGTGAC TGGGGTGAGCG 3' [10] were used, and ERIC-PCR reactions
186 were performed in a 10 μ l volume containing 5 μ l of DreamTaq Green Polymerase 2X
187 (ThermoFisher ScientificTM, Vilnius, Lithuania), 0.1 μ l of each primer, 2.8 μ l of nuclease-free
188 millipure water, and 2 μ l of DNA template. The amplification steps were as previously described
189 [10]. The generated PCR products were resolved by horizontal electrophoresis on 1.5% (wt/vol)
190 Tris-Acetate-EDTA agarose gels (Merck, Germany) with Quick-load@1-kb (Biolabs, New
191 England) and run in a 110 V electric field for 2 h 30 min. Electrophoresis gels were visualized by
192 a UV light transilluminator. Gel images were exported to GelJ software (version 2.0) for cluster
193 analyses. Metadata, phenotypic, and genotypic data were incorporated into the dendograms for
194 better clonal relatedness inference.

195 **6. Quality controls**

196 *E. coli* ATCC 35218 and *Klebsiella pneumoniae* ATCC 700603 strains were used as positive
197 controls for the *bla_{TEM}* and *bla_{SHV}* genes, respectively. For the *bla_{CTX-M}* gene, a previously whole
198 genome sequenced *E. coli* isolate (unpublished result) served as an internal quality control. *E.*
199 *coli* ATCC 35218 and *Klebsiella pneumoniae* ATCC 700603 strains were used as positive

200 controls for the *bla_{TEM}* and *bla_{SHV}* genes, respectively. For the *bla_{CTX-M}* gene, a previously whole
201 genome-sequenced *E. coli* isolate (unpublished result) served as an internal quality control.

202 **7. Data management and statistical analysis**

203 Data collected in EpiCollect® were exported to Microsoft Office Excel 2016 (Microsoft®
204 Excel). Data cleaning and data analysis were performed using R software (version 4.1.0) and
205 RStudio (version 2021.09.0). A participant was considered positive to *E. coli* or *K. pneumoniae*
206 when one colony of any of the species was detected in the samples. Likewise, a participant was
207 ESBL positive when at least one ESBL colony was detected. A participant was considered
208 multidrug resistant positive when an *E. coli* or *K. pneumoniae* isolate showed resistance to at
209 least three antibiotics from three or more families of antibiotics, with or without the presence of
210 an ESBL phenotype. The Fisher exact and Chi-square test (where appropriate) were used to
211 compare the proportions among categorical variables. Results were considered statistically
212 significant at a *p*-value < 0.05. Missing data were not considered in the analysis.

213 **RESULTS**

214 **1. Population socio-demographic and clinical characteristics in relation to colonization
215 status**

216 **1.1.Pregnant women**

217 Out of the 103 women contacted, 100 were enrolled and 93 provided samples. The mean age of
218 the included participants was 27.8 years (\pm std. 5.6 years), and all lived in urban areas. The
219 average gestational age of pregnant women was 38.9 weeks (\pm std. 4.4 weeks). Among the 93
220 women sampled, 87% (81/93) were positive for *E. coli* and/or *K. pneumoniae* (Table 1). Of these,
221 90% (73/81) were colonized by at least one MDR isolate with 52% (42/81) of these being
222 concomitantly colonized by at least one ESBL isolate (Figure 2).

223 **1.2.Neonates**

224 From the 93 mothers enrolled, 90 neonates were included and sampled. Most of them were male
225 (57%, 53/93) and the average weight was 3290 g (\pm std 644.88 g). Out of these, 25% (22/90) were
226 positive for *E. coli* and/or *K. pneumoniae* with male being more positive than female (64% vs
227 36%, p=0.47) although without statistical significance. Most of the positive neonates weighted
228 \geq 2500 g (96%, 21/22) and had a median APGAR score of 9.0 (IQR:8.0-10.0) at birth. In addition,
229 91% (19/22) neonates were colonized by MDR positive and 23% (5/22) were ESBL positive
230 (Table 2, Figure 2).

231 **1.3.Healthcare workers**

232 Twenty-five workers were enrolled in the study, with a 100% response rate. Table 3 presents the
233 different factors associated with *E. coli* and *K. pneumoniae* colonization in this population. Five
234 healthcare workers were positive for *E. coli* and/or *K. pneumoniae*. Many workers colonized with
235 *E. coli* and/or *K. pneumoniae* lived in the district of Yaoundé V (40%); and were attached to the
236 maternity ward (60%). Most admitted washing their hands five to ten times a day (80%; 4/5) and
237 only after any act on the mother or neonates (Table 3).

238 **2. Prevalence in mother-neonate dyads**

239 Twenty (91%), 19 (95%), and 12 (60%) of the 22 positive neonates were born to positive, MDR-
240 positive, and ESBL-positive mothers, respectively. Of the twenty newborns with MDR positivity,
241 18 (95%) were born to mothers with MDR positivity, while 11 (58%) were delivered to mothers
242 with ESBL positivity. Interestingly, 60% (3/5) of ESBL positive neonates were born to ESBL
243 positive mothers while all of them were delivered from MDR positive mothers although without
244 statistical significance.

245

246

247 **3. Overall prevalence of *E. coli* and *K. pneumoniae* isolates**

248 Altogether, 217 Gram-negative bacilli were isolated from the different populations, among which
249 56% were *E. coli* (95/170) and 44% *K. pneumoniae* (75/170) isolates. Most of these isolates,
250 were detected in pregnant women (82%, 140/170), of which the majority were *E. coli* (55% vs
251 45%, p=0.01). Twenty-two (16%) isolates, including 16 (73%) *E. coli* and six (27%) *K.*
252 *pneumoniae* were identified in neonates (p=0.01). Six (4%) isolates were detected from
253 healthcare workers, including one *E. coli* isolate (17%) and five *K. pneumoniae* isolates (83%).
254 Finally, only one isolate of each species was detected in the environment.

255 **4. Prevalence of *E. coli* and *K. pneumoniae* isolates in mother and neonate pairs**

256 Among the 22 isolates detected in neonates, 20 (91%) were born to positive mothers including
257 six (27%), four (18%), and eight mother-neonate pairs positive to *E. coli*, *K. pneumoniae* and a
258 combination of *E. coli* and *K. pneumoniae*, respectively. Two couple of mother and neonates
259 were positive to *E. coli* and *K. aerogenes* while two were discordant with positive neonates and
260 negative mothers.

261 **5. Antimicrobial resistance profiles of *E. coli* and *K. pneumoniae* isolates**

262 Altogether, 78% (132/170) of isolates were MDR with 51% being *E. coli* (68/132) and 49% *K.*
263 *pneumoniae* (64/132). Intriguingly, all isolates of healthcare workers were MDR, while an
264 important level of MDR-*E. coli* isolates was recorded among neonates (71%, 15/21) with strong
265 statistical significance (p=0.0002) (Figure 3). In contrast, similar prevalences of MDR-*E. coli*
266 (49%, 52/105) and MDR-*K. pneumoniae* (51%, 53/105) were detected in mothers. Interestingly,
267 of the MDR isolates detected, 44% (58/132) were concomitantly ESBL producers, most of these
268 were *K. pneumoniae* (60%; 35/58 vs 40%; 23/58) (Figure 3). MDR-ESBL-*K. pneumoniae*

269 predominated in mothers (56%, 28/50) and neonates (100%, 5/5) with high statistical significance
270 ($p<0.0001$).

271 Intriguingly, a total of 10/68 (15%) isolates were ESBL producers only, among which 60% (6/10)
272 were *E. coli* and 40% (4/10) *K. pneumoniae*. Likewise, 56% (74/132) isolates were MDR-non-
273 ESBL producers with 61% (45/74) and 39% (29/74) being MDR-non-ESBL-*E. coli* and MDR-
274 non-ESBL-*K. pneumoniae* isolates, respectively. More specifically, 94% (15/16) of MDR-non-
275 ESBL-*E. coli* isolates were recorded in neonates whereas 55% (30/55) of MDR-non-ESBL-*E.*
276 *coli* isolates were detected in mothers with high statistical significance ($p<0.0001$) (Figure 3).
277 Half (3/6, 50%) of the healthcare worker isolates were MDR-non-ESBL-*K. pneumoniae* while
278 the sole environmental *K. pneumoniae* isolate was ESBL producer only and *E. coli* was non-
279 MDR-non-ESBL.

280 Overall, isolates displayed high resistance to cotrimoxazole (83%; 141/171), doxycycline (59%;
281 100/171), and a low level of resistance to amikacin (6.43%; 11/171) (Table 4). *E. coli* was more
282 resistant to cotrimoxazole (80%) and doxycycline (58.9%), while *K. pneumoniae* was more
283 resistant to cotrimoxazole (86%).

284 **6. Prevalence of resistance genes involved in ESBL production**

285 Of the 68 ESBL-producing isolates, the *bla_{CTX-M}* (75%, 51/68) was the most frequent genes
286 followed by *bla_{TEM}* (43%, 29/68) and *bla_{SHV}* (41%, 28/68) genes (Table 5). When analysed at the
287 population level, *bla_{CTX-M}* predominated in pregnant women (48/59, 81%) while all genes had a
288 40% prevalence among neonates. The two ESBL positive isolates from healthcare workers were
289 harboured individually *bla_{CTX-M}* and *bla_{TEM}*.

290

291

292 **7. Genomic fingerprinting by ERIC-PCR**

293 ERIC profiles revealed some associations between species in different populations and probably

294 vertical transmission of *E. coli* and *K. pneumoniae* between pregnant women and neonates or

295 horizontal transmission between pregnant women, neonates, and healthcare workers.

296 The ERIC profiles of *E. coli* isolates revealed that in cluster E4 a pair of mother-neonate isolates

297 (PO264B - N2264B) collected on the same date having 100% similarity although they displayed

298 discordant MDR phenotype. Furthermore, this mother-neonate isolate pair shared a common

299 ancestor with isolates from another mother (PO231A) and two other neonates (N2220 and

300 N2234) collected seven days before this pair (Figure 4). In contrast, in cluster E7, a 100%

301 similarity was observed between isolates originating from a mother (PO279C) and a neonate born

302 to another mother (N2292) with a four-day collection lapse and both being MDR. These

303 discordant mother-neonate isolates further shared a common ancestor with a caregiver

304 (HW002A) collected 48 hours before the neonate and 48 hours after the mother (Figure 4).

305 Intriguingly, a triplet of neonatal isolates (N2249A, N2247, N2246) shared 100% similarity with

306 a maternal isolate (PO284A) collected one week apart and had a common ancestor with a

307 neonatal isolate (N2235) collected two days before the neonatal isolates. Besides, the mother-

308 neonate pair relatedness, *E. coli* isolates from mother-mother and neonate-neonate pairs sharing

309 100% similarity were observed in cluster E9-E13 (Figure 4).

310 The ERIC profiles of *K. pneumoniae* revealed that none of the neonatal *K. pneumoniae* isolates

311 were linked to the respective maternal isolates. Such discordance was observed for the neonatal

312 isolates NN2223B (K6), NN2290 (K7), N2278 (K9) and N22218B (K10) sharing common

313 ancestors with other isolates from other mothers, PO266A (K6), PO290 (K7), PO284C (K9) and

314 PO299B. Interestingly, NN2276 (K9) shared a common ancestor with an isolate detected from a
315 worker (HCW008A) (Figure 5).

316 **DISCUSSION**

317 There is limited information about the burden and transmission of resistant bacteria in mothers
318 and neonates in Cameroon, yet these are critical to implementing tailored prevention measures
319 and achieving the United Nations Sustainable Development Goal (SDG) target 3.2.2. that aims
320 for countries to have ≤ 12 neonatal deaths/1000 live births by 2030 (3, 4). Cameroon needs to
321 increase its efforts by three to five times to expect to achieve this target by 2030 (1).

322 This study that aimed to determine the phenotypic and molecular features of *E. coli* and *K. pneumoniae* in a labour ward in Yaoundé, Cameroon revealed an elevated prevalence (rates
323 ranging from 20-87%) of colonization by *E. coli* and/or *K. pneumoniae*. One of the most striking
324 findings of this study was the high prevalence of MDR in pregnant women (90%, 73/81) and
325 neonates (91%, 19/22). This unexpected, elevated prevalence of MDR can be explained by the
326 absence of antimicrobial stewardship policies that favours irrational use of antibiotics in the
327 human health sector, self-medication and over the counter supply of antibiotics. Additionally, the
328 suboptimal water, sanitation, and hygiene (WASH), poor or non-existence of infection prevention
329 and control (IPC) measures programme in the country and healthcare settings, coupled with
330 absence of surveillance and monitoring system contribute to facilitate the emergence and
331 dissemination of resistant bacteria. The detection of MDR-*E. coli* and MDR-*K. pneumoniae*
332 might worsen the prognosis of neonates in case of infections.

334 MDR-*E. coli* and MDR-*K. pneumoniae* have often been involved in life-threatening neonatal
335 infections, particularly sepsis, and were identified as the leading neonatal killers in 2019 (5).

336 There is limited available data from Africa, our findings are similar to those of a Ghanaian study
337 where 99% of Gram-negative bacilli growth was recorded in hospital environments, with over
338 80% of ESBL-producing isolates originating from the obstetrics and gynecology wards (15).
339 However, the respective prevalences of *E. coli* (55%) and *K. pneumoniae* (45%) in pregnant
340 women in our study are higher than those obtained in a study investigating vaginosis in pregnant
341 women in Ethiopia with 25% *E. coli* and 2.3% *K. pneumoniae* (16). These differences may be
342 explained by the collection methods used, the type of sample, and the different geographical
343 locations.

344 On the other hand, the respective prevalence of *E. coli* and/or *K. pneumoniae* in neonates were
345 73% and 27%. These results are contradictory to those obtained in a study assessing the
346 prevalence and risk factors of antimicrobial resistance in neonatal sepsis in Ethiopia where *K.*
347 *pneumoniae* (79%) was the leading Gram-negative bacteria followed by *E. coli* (8%) (16). This
348 difference may be explained by the follow-up period of neonates until 60 days after birth in the
349 Ethiopian study. Interestingly, 91% (20/22) of the positive neonates were born to positive
350 mothers, 27% and 18% of whom born to *E. coli* and *K. pneumoniae* positive mothers suggesting
351 a probable vertical transmission from mothers to their neonates. This finding is in staggering
352 contrast with a well-powered systematic review conducted in Africa that revealed a 27%
353 prevalence of MDR-Gram-negative bacteria transmission from mothers to neonates, and 19%
354 prevalence of neonatal ESBL-*Enterobacteriales* colonization (9). The scarcity of studies from
355 Central African countries in this systematic review could explain this discrepancy.

356 Of great concern, was the high prevalence of MDR-ESBL *K. pneumoniae* among neonates
357 (100%), healthcare workers (83%) and mothers (60%). The fact that most healthcare workers
358 admitted washing their hands between five to ten times a day and only after a medical act on a

359 mother or a neonate gives credence to the hypothesis that sub-optimal IPC could contribute to the
360 persistence and dissemination of MDR-ESBL-*K. pneumoniae* in the environment and
361 subsequently to mothers and neonates. Acknowledging that hand hygiene has a significant role in
362 reducing bacterial infections in healthcare settings when implemented adequately and timely, the
363 World Health Organisation developed the five moments for hand hygiene guideline (17). In this
364 guideline, the first two moments for hand hygiene that are essential to prevent the transmission of
365 germs in hospital are before touching a patient (moment 1) and before performing a procedure on
366 a patient (moment 2) (17). *K. pneumoniae* which is capable of resisting on healthcare workers'
367 hands or in the environment for a long period of time, could easily spread from healthcare
368 workers or the environment to mothers or neonates when hand hygiene or hospital disinfection is
369 not well implemented especially for the remaining moments, after a procedure (moment 3), after
370 touching a patient (moment 4) and after touching patient surrounding (moment 5) (17, 18).
371 This can further explain the fact that one worker despite admitting washing his/her hand more
372 than 30 times per day was colonised by MDR-ESBL-producing *K. pneumoniae*. It is thus
373 plausible to surmise that healthcare workers by neglecting the moments 3-5 contribute
374 inadvertently to the contamination of hospital environment and subsequent spread of resistant
375 bacteria to mothers and neonates. This is particularly true for *K. pneumoniae* compared to *E. coli*
376 given the presence of capsular membrane that ensure its survival in extreme environmental
377 conditions. Smit et al. (2018) demonstrated that ESBL-*K. pneumoniae* were transmitted between
378 humans and 22% of neonate infections were due to environmental source (19). Furthermore,
379 Dramowski et al. (2022) emphasized the importance of WASH and IPC in the early and heavy
380 bacterial colonization of neonates in resource-limited settings and recommended sustained
381 neonatal IPC and surveillance programs in neonatal units in these settings (20). Healthcare

382 workers colonized with MDR-ESBL isolates could thus contribute to the ongoing transmission of
383 resistant bacteria to neonates where they could subsequently cause life-threatening neonatal
384 infections such as sepsis, meningitis or pneumoniae.

385 Infections caused by ESBL-producing *E. coli* and *K. pneumoniae* may be co-resistant to many
386 other classes of antibiotics, resulting in the emergence of so-called multidrug-resistant bacteria
387 (resistance to at least one antibiotic from three or more antibiotic families) (21). Both ESBL
388 production and MDR is threatening considerably the management of neonatal infections and the
389 prognosis of neonates (22). In this study, *bla_{CTX-M}*, *bla_{TEM}*, and *bla_{SHV}* were widely detected at an
390 overall prevalence of 75%, 43% and 42%, respectively. The *bla_{CTX-M}* gene was most frequently
391 isolated in women (81.35%) while *bla_{CTX-M}* and *bla_{TEM}* co-dominated among neonates and
392 healthcare workers. These results were different from those found in Sudan where the
393 predominant gene was *bla_{TEM}* (86%) (23). This difference could be due to the abusive and
394 inappropriate use of β-lactam antibiotics, especially cefotaxime in Cameroon.

395 ERIC genotypes revealed significant associations between isolates from pregnant women,
396 neonates, and healthcare workers for both *E. coli* and *K. pneumoniae*. Only one dyad of mother-
397 neonate *E. coli* isolates (PO264B–N2264B) was detected with 100% similarity, and these shared
398 a common ancestor with a batch of isolates originating from a mother (PO231A) and two other
399 neonates (N2220 and N2234) collected seven days apart. Most alarming was that all these
400 neonatal isolates of this cluster were MDR-non-ESBL producers while maternal isolates were
401 neither MDR nor ESBL. These results call into question the hand hygiene of the nursing staff and
402 the environment in the delivery room. In fact, the discrepancies observed between neonatal and
403 maternal isolates may be due to either temporary or permanent hand colonization of worker by *E.*

404 *coli* or *K. pneumoniae* upon a contact with colonized neonates or mothers and the contaminated
405 hospital environment.

406 The 100% similarity between two MDR-ESBL-*E. coli* isolates from two mothers collected on the
407 same date raises the issue about the quality of the maternity ward environment, especially that of
408 the labour room. It reveals the fluid transmission of bacteria within this maternity ward and
409 highlights the limited prevention control measures notably hand hygiene existing in this hospital
410 ward where bacteria can spread from one neonate to another or from one mother to another
411 neonate horizontally via healthcare workers. Although we did not find significant bacterial loads
412 in the environment in this study, it is important to note that the environment cannot be
413 overlooked as a risk factor for contamination of mothers, neonates, and healthcare workers.

414 Notwithstanding, this study has several limitations. First, the limited sample size precludes any
415 robust conclusion on the real burden of MDR and ESBL-*E. coli* and *K. pneumoniae* in all sources
416 at the country level. Second, neonates could not be followed up to assess the outcome of this
417 carriage by these resistant bacteria. Third, we could not identify the source of contamination nor
418 ascertain the mode (vertical vs hospital-acquired), route of transmission especially in mothers and
419 neonates. Fourth, it was not possible to investigate all resistance genes encoding for ESBL and
420 MDR production. Finally, by investigating only the labour room, it is impossible to know if the
421 carriage status of mothers was the same throughout the pregnancy. Despite these limitations, the
422 study contributes to fill significant data gaps on the burden and genetic characteristics of *E. coli*
423 and *K. pneumoniae* in a vulnerable population in Cameroon.

424 **CONCLUSION**

425 This study suggests that MDR- and ESBL-*E. coli* and *K. pneumoniae* are actively circulating in
426 labour ward with high prevalence in this confessional hospital of Yaoundé. It urges the
427 imperative for stringent infection prevention and control measures particularly hand hygiene, in
428 conjunction with antimicrobial stewardship programmes in the country. It advocates for the
429 implementation of routine screening for multidrug-resistant and/or ESBL-producing
430 *Enterobacteriales* at least among at-risk pregnant women and neonates, as these could contribute
431 to save lives in case of life-threatening neonatal infections. More advanced genomic studies are
432 required and should be implemented to fully elucidate the transmission routes and sources of
433 these resistant bacteria in Cameroon.

434 **Financial disclosure**

435 The study was funded by the Thrasher Research Fund through the Thrasher Early Career Award
436 awarded to FLL (Award number 01364). The funder had no role in the study design, preparation
437 of the manuscript nor the decision to submit the work for publication.

438 **Competing interest statement**

439 The authors declare that there is no conflict that could be construed as financial interest.

440 **Data availability**

441 All data generated during this study are included in the article.

442 **Acknowledgements**

443 We are grateful to the participants who provided samples for analysis in this study.

444 **Author Contributions**

445 **Conceptualization:** Axelle Njeuna, Luria Leslie Founou, Ariel Blocker, Stephen Bentley and
446 Lucien Honoré Etame Sone.

447 **Data curation:** Axelle Njeuna, Patrice Landry Koudoum and Aurelia Djemako Mbossi

448 **Formal analysis:** Axelle Njeuna, Luria Leslie Founou

449 **Investigation:** Axelle Njeuna, Patrice Landry Koudoum and Aurelia Mbossi.

450 **Project administration:** Luria Leslie Founou, Raspail Carrel Founou, Lucien Etame Sone.

451 **Software:** Axelle Njeuna, Patrice Landry Koudoum and Luria Leslie Founou.

452 **Supervision :** Luria Leslie Founou, Raspail Carrel Founou, and Lucien Honoré Etame Sone.

453 **Writing – original draft:** Axelle Njeuna, Luria Leslie Founou

454 **Writing – review & editing:** Luria Leslie Founou, Raspail Carrel Founou, Stephen Bentley,

455 Ariel Blocker, Lucien Honoré Etame

456 **Approval and validation:** All authors

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472 **References**

473

474 1. Sharow D, Hug L, You D, Alkema L, Black R, Cousens S, et al. Global, regional, and
475 national trends in under-5 mortality between 1990 and 2019 with scenario-based projections until
476 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation. The
477 Lancet Global Health. 2022;10(2):e195-e206.

478 2. IHME. Health-related SDGs Seattle, WA: IHME, University of Washington; 2023
479 [Available from: <http://vizhub.healthdata.org/sdg>.

480 3. EWEC. The global strategy for women's, children's and adolescents' health (2016–2030).
481 2015.

482 4. UNDESA. The Sustainable Development Goals Report 2019: United Nations; 2019.

483 5. Okomo U, Akpalu ENK, Le Doare K, Roca A, Cousens S, Jarde A, et al. Aetiology of
484 invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a
485 systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. The
486 Lancet Infectious Diseases. 2019;19(11):1219-34.

487 6. Okomo UA, Darboe S, Bah SY, Ayorinde A, Jarju S, Sesay AK, et al. Maternal
488 colonization and early-onset neonatal bacterial sepsis in the Gambia, West Africa: a genomic
489 analysis of vertical transmission. Clinical Microbiology and Infection. 2022.

490 7. Sands K, Spiller OB, Thomson K, Portal EAR, Iregbu KC, Walsh TR. Early-Onset
491 Neonatal Sepsis in Low- and Middle-Income Countries: Current Challenges and Future
492 Opportunities. Infection and drug resistance. 2022;15:933-46.

493 8. Bulabula ANH, Dramowski A, Mehtar S. Maternal colonization or infection with
494 extended-spectrum beta-lactamase-producing Enterobacteriaceae in Africa: A
495 systematic review and meta-analysis. International Journal of Infectious Diseases. 2017;64:58-
496 66.

497 9. Bulabula ANH, Dramowski A, Mehtar S. Transmission of multidrug-resistant Gram-
498 negative bacteria from colonized mothers to their infants: a systematic review and meta-analysis.
499 Journal of Hospital Infection. 2020;104(1):57-67.

500 10. Laxminarayan R, Bhutta ZA. Antimicrobial resistance: a threat to neonate survival. The
501 Lancet Global Health. 2016;4(10):e676-e7.

502 11. Fitchett EJA, Seale AC, Vergnano S, Sharland M, Heath PT, Saha SK, et al.
503 Strengthening the Reporting of Observational Studies in Epidemiology for Newborn Infection
504 (STROBE-NI): an extension of the STROBE statement for neonatal infection research. The
505 Lancet Infectious diseases. 2016;16(10):e202-e13.

506 12. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0
507 . 2022.

508 13. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI
509 supplement M100. Wayne, Pennsylvania: USA: CLSI; 2020.

510 14. Dimani BD, Founou RC, Zemtsa JR, Mbossi A, Koudoum PL, Founou LL, et al. Faecal
511 carriage of multidrug-resistant and extended-spectrum β -lactamase-producing Enterobacteriales
512 in people living with HIV in Yaoundé, Cameroon. Journal of Global Antimicrobial Resistance.
513 2023;35:26-34.

514 15. Acolatse JEE, Portal EAR, Boostrom I, Akafity G, Dakroah MP, Chalker VJ, et al.

515 Environmental surveillance of ESBL and carbapenemase-producing gram-negative bacteria in a

516 Ghanaian Tertiary Hospital. *Antimicrobial Resistance & Infection Control*. 2022;11(1):49.

517 16. Yalew GT, Muthupandian S, Hagos K, Negash L, Venkatraman G, Hagos YM, et al.

518 Prevalence of bacterial vaginosis and aerobic vaginitis and their associated risk factors among

519 pregnant women from northern Ethiopia: A cross-sectional study. *PLoS One*.

520 2022;17(2):e0262692.

521 17. WHO. WHO guidelines on hand hygiene in health care. WHO guidelines on hand

522 hygiene in health care2009. p. 270-.

523 18. Perovic O, Singh-Moodley A, Dusé A, Bamford C, Elliott G, Swe-Han KS, et al.

524 National sentinel site surveillance for antimicrobial resistance in *Klebsiella pneumoniae* isolates

525 in South Africa, 2010 - 2012. *South African medical journal = Suid-Afrikaanse tydskrif vir*

526 *geneeskunde*. 2014;104(8):563-8.

527 19. Smit PW, Stoesser N, Pol S, van Kleef E, Oonsivilai M, Tan P, et al. Transmission

528 Dynamics of Hyper-Endemic Multi-Drug Resistant *Klebsiella pneumoniae* in a Southeast Asian

529 Neonatal Unit: A Longitudinal Study With Whole Genome Sequencing. *Front Microbiol*.

530 2018;9:1197.

531 20. Dramowski A, Aucamp M, Beales E, Bekker A, Cotton MF, Fitzgerald FC, et al.

532 Healthcare-Associated Infection Prevention Interventions for Neonates in Resource-Limited

533 Settings. *Frontiers in Pediatrics*. 2022;10.

534 21. Sivaraman GK, Rajan V, Vijayan A, Elangovan R, Prendiville A, Bachmann TT.

535 Antibiotic Resistance Profiles and Molecular Characteristics of Extended-Spectrum Beta-

536 Lactamase (ESBL)-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolated From Shrimp

537 Aquaculture Farms in Kerala, India. *Front Microbiol.* 2021;12:622891.

538 22. Wattal C, Kler N, Oberoi JK, Fursule A, Kumar A, Thakur A. Neonatal Sepsis: Mortality

539 and Morbidity in Neonatal Sepsis due to Multidrug-Resistant (MDR) Organisms: Part 1. *Indian J*

540 *Pediatr.* 2020;87(2):117-21.

541 23. Dirar MH, Bilal NE, Ibrahim ME, Hamid ME. Prevalence of extended-spectrum β -

542 lactamase (ESBL) and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes

543 among Enterobacteriaceae isolates from patients in Khartoum, Sudan. *Pan Afr Med J.*

544 2020;37:213.

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565 **Table 1.** Distribution of socio-demographic and clinical characteristics among pregnant women
 566 in relation with the colonization of *E. coli* and/or *K. pneumoniae*

Variables		Positive*, n (%)	p-value	MDR positive n (%)	p-value	ESBL positive n (%)	p-value
Overall (N= 93)		81(87.09)	-	73 (90.12)	-	42(45.16)	-
Age (years)	[15 -24]	25 (30.86)	0.9972	21 (31.82)	0.155	15 (35.71)	0.3984
	[25-34]	46 (56.79)		35 (53.03)		19 (45.25)	
	[35-44]	10 (12.35)		10 (15.15)		8 (1.04)	
Residence	Urban	81 (100)	/	73 (100)	/	42 (100.00)	/
Education	Primary	3 (3.70)	0.2315	3 (4.11)	0.785	2 (4.76)	0.4129
	Secondary	53 (65.43)		48 (65.75)		30 (71.43)	
	High school	25 (30.86)		22 (30.14)		10 (23.81)	
Person living at home	[1-7]	67 (8.71)	0.4272	52 (78.79)	0.045	34 (80.96)	0.0294
	[8-14]	13 (16.04)		13 (19.69)		8 (19.04)	
	[15-21]	1 (1.25)		1 (1.52)		0	
Occupation	Others	23 (28.40)	0.7252	20 (27.40)	1.000	11 (26.19)	0.3253
	Seller	3 (3.70)		3 (4.11)		3 (7.14)	
	Student	26 (32.10)		23 (31.51)		15 (35.71)	
	Farmer	1 (1.23)		1 (1.37)		0 (0)	
	Official	6 (7.41)		6 (8.22)		4 (9.52)	
	housewife	20 (24.69)		18 (24.66)		9 (21.43)	
	Healthcare workers	2 (2.47)		2 (2.74)		0 (0)	
Average monthly income (CFA Francs)	< 30.000	45 (55.56)	0.8633	40 (54.79)	1.000	25 (59.52)	0.2257
	30.000– 60.000	16 (19.75)		14 (19.18)		10 (23.81)	
	60.000– 90.000	14 (17.28)		13 (17.81)		5 (11.90)	
	90.000– 120.000	2 (2.47)		2 (2.74)		1 (2.38)	
	120.000– 150.000	3 (3.70)		3 (4.11)		0 (0)	
	> 150. 000	1 (1.23)		1 (1.37)		1 (2.38)	
Animal contact	No	61 (75.31)	0.2860	54 (73.97)	0.672	31 (73.81)	0.7454
	Yes	20 (24.69)		19 (26.03)		11 (26.19)	
Drinking water	Borehold	52 (64.20)	0.0074	48 (65.75)	0.100	29 (69.05)	0.5346
	Mineral	5 (6.17)		3 (4.11)		1 (2.38)	
	Tap water	18 (22.22)		17 (23.29)		9 (21.43)	
	Source	6 (7.41)		5 (6.85)		3 (7.14)	

567

568

569

570

571

572

573

574 **Table 1. Continued**

Variable		Positive* n (%)	P-value	MDR positive& n (%)	P-value	ESBL positive\$ n (%)	P-value
Hospitalisation	No	75 (92.59)	0.28	69 (94.52)	0.20	37 (88.10)	0.20
	Yes	6 (7.41)		4 (5.48)		5 (11.90)	
Antibiotic use	No	76 (93.83)	0.22	68 (93.15)	0.67	40 (95.24)	0.66
	Yes	5 (6.17)		5 (6.85)		2 (4.76)	
Status to infectious diseases	VIH	2 (2.47)	0.63	2 (2.74)	0.54	1 (2.38)	0.54
	Hepatite B	2 (2.47)		2 (2.74)		2 (4.76)	
	Chlamydia	1 (1.23)		1 (1.32)		0 (0)	
	None	76 (93.83)		68 (93.15)		39 (92.86)	
Gravidity	Primipara	33 (40.74)	1.00	30 (41.10)	0.62	16 (38.10)	0.62
	Multipara	48 (59.26)		43 (58.90)		26 (61.90)	
Death in utero	No	80 (98.77)	1.00	72 (98.63)	0.48	42 (100.00)	0.48
	Yes	1 (1.23)		1 (1.37)		0 (0)	
Abortion	No	51 (62.96)	0.53	44 (60.27)	0.11	23 (54.76)	0.11
	Yes	30 (37.04)		29 (39.73)		19 (45.24)	
Stillbirth	No	73 (90.12)	1.00	68 (93.15)	0.03	37 (88.10)	0.71
	Yes	8 (9.88)		5 (6.85)		5 (11.90)	
Gestational age	Min / Max	0 / 42.0	0.77	0 / 42.0	0.93	32.0 / 42.0	0.93
	Med [IQR]	40.0 [38.0;40.0]		39.0 [38.0;40.0]		40.0 [38.0;40.0]	
	Mean (std)	38.8 (4.7)		38.7 (4.9)		39.2 (2.0)	
Antenatal care visit	Min / Max	0/9.0	0.54	0/9.0	0.66	0/8.0	0.25
	Med [IQR]	4.0 [3.0;5.0]		4.0 [3.0; 5.0]		4.0 [3.0;5.0]	
	Mean (std)	4.1 (1.7)		4.1 (1.7)		3.8 (1.6)	
No. birth	Min / Max	1.0/5.0	0.31	1.0/5.0	0.83	1.0/5.0	0.01
	Med [IQR]	2.5[1.0;3.2]		3.0[1.5;3.5]		3.0[2.0;4.0]	
	Mean (std)	2.6 (1.3)		2.6 (1.3)		3.0 (1.3)	

*Colonization by *E. coli* and/or *K. pneumoniae*, &Colonization by MDR-*E. coli* and/or MDR-*K. pneumoniae*, \$Colonization by ESBL-*E. coli* and/or ESBL-*K. pneumoniae*, ESBL: Extended spectrum β-lactamase, MDR: Multidrug resistance

575

576

577

578

579

580

581

582 **Table 2. Colonization status in relation to socio-demographic and clinical characteristics of**
 583 **neonates**

Variable		Positive* n (%)	P- value	MDR positive n (%)	P- value	ESBL positive n (%)	P- value
Overall (N= 90)		22 (24.44)	-	20(90.91)	-	5 (22.73)	-
Sex	Male	14 (63.64)	0.47	12 (60)	0.52*	2 (40.00)	0.31
	Female	8 (36.36)		8 (40)		3 (60.00)	
Gestational age	Min / Max	32.0 / 42.0	0.64	32.0 / 42.0	0.41	32.0 / 40.0	0.20
	Med [IQR]	39.5 [38.0;40.0]		39.0 [38.0;40.0]		39.0 [36.0;39.0]	
	Mean (std)	39.0 (2.2)		38.9 (2.3)		37.2 (3.3)	
Weight	< 2500g	1(4.54)	0.90	1(7.14)	0.33	0(0)	0.5907
	≥2500g	21(95.46)		13(92.86)		5(100)	
APGAR score at birth	Min / Max	0 / 10.0	0.1	0 / 10.0	0.40	9.0 / 10.0	0.0396
	Med [IQR]	9.0 [8.0;10.0]		9.0 [8.0;10.0]		10.0 [10.0;10.0]	
	Mean (std)	8.6 (2.2)		8.7 (2.3)		9.8 (0.4)	
APGAR score after 5 min	Min / Max	0 / 10.0	0.98	0 / 10.0	0.57	10.0 / 10.0	0.3245
	Med [IQR]	10.0 [10.0;10.0]		10.0 [10.0;10.0]		10.0 [10.0;10.0]	
	Mean (std)	9.5 (2.1)		9.4 (2.2)		10.0 (0)	
E. coli or K. pneumoniae Positive mother	No	2 (9.09)	0.72	1 (5)	0.18	0 (0)	1.00
	Yes	20 (90.91)		19 (95)		5 (100.00)	
ESBL status of mother	No	8 (40)	0.36#	8 (42.11)	1.00†	2 (40)	1.00
	Yes	12(60)		11 (57.89)		3 (60)	
MDR status of mother	No	1 (5)	0.67#	1 (5.26)	1.00†	0	1.00
	Yes	19 (95)		18 (94.74)		5 (100)	

584 *Colonization by *E. coli* and/or *K. pneumoniae*, &Colonization by MDR-*E. coli* and/or MDR-*K. pneumoniae*, \$Colonization by
 585 ESBL-*E. coli* and/or ESBL-*K. pneumoniae*, ESBL: Extended spectrum β-lactamase, MDR: Multidrug resistance, #Missing values
 586 (n=02) were not included in the analysis, †Missing values (n=01) were not included in the analysis, Med: Median, IQR:
 587 Interquartile range, Std: Standard deviation, Min: minimum, Max: Maximum

588

589

590

591

592
593
594
595
596
597

598 **Table 3. Distribution of colonization status in relation to socio-demographic characteristics**
599 **of healthcare workers**

Variable		Positive* n (%)	P-value	ESBL positive n (%)	P-value	MDR positive, n (%)	P- value
Overall (N= 25)		5 (20)	-	3 (60)	-	5 (100)	-
Age	Min / Max	1.0 / 15.0	0.38	1.0 / 15.0	1.00	1.0 / 15.0	-
	Med [IQR]	7.0 [2.0;9.0]		7.0 [4.0;11.0]		7.0 [2.0;9.0]	
	Mean (std)	6.8 (5.7)		7.7 (7.0)		6.8 (5.7)	
Service	Others	0 (0)	0.53	0 (0)	0.40	0 (0)	-
	Operating room	2 (40)		2 (66.67)		2 (40)	
	Consultation	0 (0)		0 (0)		0 (0)	
	Hospitalisation	0 (0)		0 (0)		0 (0)	
	Maternity	3 (60)		1 (33.33)		3 (60)	
Animals	No	4 (80)	0.34	2 (66.67)	1.00	4 (80)	-
	Yes	1 (20)		1 (33.33)		1 (20)	
Frequency of hand washing per day	1 - 5 times per day	0 (0)	0.36	0 (0)	1.00	0 (0)	-
	5 - 10 times per day	4 (80)		2 (66.67)		4 (80)	
	10 - 30 times per day	0 (0)		0 (0)		0 (0)	
	more than 30 times	1 (20)		1 (33.33)		1 (20)	
Time to wash your hands	After any procedure on a pregnant woman or newborn	4 (80)	0.36	2 (66.66)	1.00	4 (80)	-
	Before and after any procedure in a pregnant woman or newborn	1 (20)		1 (33.33)		1(20)	
Residence District	YAOUNDE 1	0 (0)	0.11	0 (0)	1.00	0 (0)	-
	YAOUNDE 2	1 (20)		0 (0)		1 (20)	
	YAOUNDE 3	0 (0)		0 (0)		0 (0)	
	YAOUNDE 4	1 (20)		1 (33.33)		1 (20)	
	YAOUNDE 5	2 (40)		1 (33.33)		2 (40)	
	YAOUNDE 6	1 (20)		1 (33.33)		1 (20)	
	YAOUNDE 7	0 (0)		0 (0)		0 (0)	
Taking medication	No	5 (100)	0.54	3 (100)	1.00	5 (100)	-
	Yes	0 (0)		0 (0)		0 (0)	
Knowledge of bacterial resistance	No	1 (20)	1.00	1 (33.33)	1.00	5 (100)	-
	Yes	4 (80)		2(66.67)		0(0)	

600 *Refers to the colonization by *E. coli* and/or *K. pneumoniae*

601

602
603
604
605
606
607

608 **Table 4. Distribution of antibiotic resistance among *E. coli* and *K. pneumoniae* isolates**

Bacterial Species (n)	β-lactams, n (%)						Other antibiotic families, n(%)					
	AUG	CXM	CTX	CAZ	FEP	FOX	AK	GEN	DOX	CIP	CHL	TMP/SXT
<i>E. coli</i> (95)	21 (22.1)	31 (39.7)	30 (31.6)	15 (15.8)	21 (22.1)	7 (22.1)	6 (6.32)	10 (10.5)	56 (58.9)	17 (17.9)	21 (22.1)	76 (80)
<i>K. pneumonia</i> (75)	43 (56.57)	45 (59.21)	32 (42.10)	25 (32.89)	28 (36.84)	28 (36.84)	5 (6.57)	18 (23.68)	44 (57.89)	20 (26.31)	22 (28.94)	65 (85.52)
Total (170)	64 (37.42)	76 (44.44)	62 (36.25)	40 (23.39)	49 (28.65)	35 (20.46)	11 (6.43)	28 (16.37)	100 (58.47)	37 (21.64)	43 (25.14)	141 (82.45)

609
610 AUG: amoxicillin – clavulanic acid; CXM: Cefuroxime; CTX : Cefotaxime CAZ : Ceftazidime ; FEP : Cefepime ;
611 FOX : Cefoxitin; AK : Amikacin ; GEN : Gentamicin ; DOX : Doxycycline ; CIP : Ciprofloxacin ; CHL :
612 chloramphenicol ; TMP/SXT : Trimethoprim-sulfamethoxazole (cotrimoxazole).
613

614
615
616
617
618
619
620
621
622
623
624
625
626

627

628

629

630 **Table 5.** Prevalence of β -lactamase resistance genes among ESBL-positive isolates according to
631 the source of isolation

SOURCE	<i>bla</i> _{CTX-M} , n (%)	<i>bla</i> _{TEM} , n (%)	<i>bla</i> _{SHV} , n (%)
Overall N=68 (n)	51 (75)	29 (42.64)	28 (41.17)
Pregnant women (59)	48 (81.35)	25 (42.37)	26 (44.06)
Newborns (5)	2(40)	2(40)	2 (40)
Healthcare workers (2)	1 (50)	1 (50)	0
Environment (1)	0	1(100)	0

632

633

634

635

636

637

638

639

640

641

642

643


644

645

646

647

648 **Figures**



649

650 **Figure 1:** Agarose gel (1.5%) electrophoresis of PCR amplified genes of selected isolates. L :
651 100 bp Ladder ; PC : Positive control ; NC : Negative control ; Isolates: P0281, P0249, P0222,
652 POOL 2B, P0201A, P0244B, P0219A, P0280A, P0259A, HCW025A, P0229A, PO271A.

653

654


655

656

657

658

659



660

661 **Figure 2.** Flow chart summarizing mothers' and neonates' recruitment, screening and
662 colonization status.

663


664

665

666

667

668



669

670 **Figure 3:** Distribution of *E. coli* and *K. pneumoniae* (A), MDR-*E. coli* and MDR-*K. pneumoniae* (b), MDR-ESBL-*E. coli* and MDR-ESBL-*K. pneumoniae* (C), and MDR-non-ESBL-*E. coli* and MDR-non-ESBL-*K. pneumoniae* (D) isolates in mothers and neonates.

671

672

673

674

675

676




Figure 4: Genotypic relationship of *E. coli* strains (n = 93) detected from mothers, neonates, healthcare workers and the environment. Dendogram generated by GelJ using UPGMA method and the Dice similarity coefficient.




Figure 5: Genotypic relationship of *K. pneumoniae* isolates (n = 71) detected from mothers, neonates, healthcare workers and the environment. Dendogram generated by GelJ using UPGMA method and the Dice similarity coefficient.

679

680

681

682 **Supporting Information**

683

684 **Table S1.** List of selected environmental sampling sites

685

686

687

688

689

690

691